|

obrixtamig Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Pipeline

Phase 3: 2

Top Sponsors

  • Boehringer Ingelheim2

Indications

  • Cancer2
  • Extrapulmonary Neuroendocrine Cancer (epNEC)1
  • Small Cell Lung Cancer (SCLC)1
  • Extensive Stage Small Cell Lung Cancer (ES-SCLC)1
  • Lung Cancer1

Mobile, Alabama1 trial

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Infirmary Cancer Care

Phase 3

Scottsdale, Arizona1 trial

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Mayo Clinic

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.